DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Di Leo A, Seok Lee K, Ciruelos E.
BELLE-3: a phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment. San Antonio Breast Cancer Symposium 2016; San Antonio, TX, USA; Abstract S4-07.
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.